Fresenius Medical Care AG & Co. (NYSE:FMS) Given a $62.00 Price Target by SunTrust Banks Analysts

SunTrust Banks set a $62.00 target price on Fresenius Medical Care AG & Co. (NYSE:FMS) in a report published on Thursday, December 21st. The brokerage currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. DZ Bank reiterated a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, November 13th. Morgan Stanley cut shares of Fresenius Medical Care AG & Co. from an overweight rating to an equal weight rating in a research report on Monday, December 11th. Royal Bank of Canada restated a hold rating and issued a $44.00 price objective on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, September 13th. Finally, Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. from a sell rating to a hold rating and set a $53.00 price objective on the stock in a research report on Monday, October 9th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $55.67.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) opened at $54.53 on Thursday. Fresenius Medical Care AG & Co. has a fifty-two week low of $40.02 and a fifty-two week high of $55.30. The company has a current ratio of 1.22, a quick ratio of 0.98 and a debt-to-equity ratio of 0.55. The stock has a market cap of $33,120.00, a price-to-earnings ratio of 22.26, a PEG ratio of 2.27 and a beta of 0.45.

Large investors have recently bought and sold shares of the stock. UBS Asset Management Americas Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after buying an additional 81 shares in the last quarter. Pacer Advisors Inc. bought a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth approximately $179,000. FFT Wealth Management LLC bought a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth approximately $201,000. HPM Partners LLC bought a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth approximately $221,000. Finally, YorkBridge Wealth Partners LLC lifted its stake in shares of Fresenius Medical Care AG & Co. by 19.4% in the second quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after buying an additional 749 shares in the last quarter. 3.03% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Fresenius Medical Care AG & Co. (NYSE:FMS) Given a $62.00 Price Target by SunTrust Banks Analysts” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/14/fresenius-medical-care-fms-given-a-62-00-price-target-at-suntrust-banks.html.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply